论文部分内容阅读
伊马唑呾(lmazodan)是Ⅲ型磷酸酯酶的选择性抑制剂,可提高细胞内cAMP水平,增强心肌收缩力,增加心排量,降低肺楔压和外周血管阻力。本药半衰期15～25小时,可以每日给药2次。本文观察长期使用本药的效果和安全性。本试验由多中心参加,按照随机双盲的方式进行,为期12周。对象为 59±9.7岁的147(男128、女19)例慢性心衰患者,因呼吸困难或疲劳而活动受限,活动平板运动时间506±145秒,左室射血分数23±10％。A组44例服安慰剂。B组34例服本药2mg,bid。C组37例服本药 5mg,bid。D组32
Lmazodan is a selective inhibitor of type III phosphatase that increases intracellular cAMP levels, increases myocardial contractility, increases cardiac output, and decreases pulmonary wedge pressure and peripheral vascular resistance. The half-life of the drug 15 to 25 hours, can be administered twice daily. This article observed the long-term use of the drug effect and safety. The trial was attended by multiple centers, conducted in a randomized double-blind manner for 12 weeks. 147 (male 128, female 19) patients with chronic heart failure who were 59 ± 9.7 years of age had limited mobility due to dyspnea or fatigue. Their treadmill exercise time was 506 ± 145 seconds and their left ventricular ejection fraction was 23 ± 10%. A group of 44 patients taking placebo. B group of 34 patients taking the drug 2mg, bid. C group of 37 patients taking the drug 5mg, bid. Group D 32